ELN Human shRNA Plasmid Kit (Locus ID 2006)

CAT#: TL313226

ELN - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

Specifications

Product Data

• Locus ID: 2006
• Synonyms: ADCL1; SVAS; WBS; WS
• Vector: pGFP-C-shLenti
• E. coli Selection: Chloramphenicol
• Mammalian Cell Selection: Puromycin
• Format: Lentiviral plasmids
• Kit Components: ELN - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 2006). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: NM_000501, NM_001081752, NM_001081753, NM_001081754, NM_001081755, NM_001278912, NM_001278913, NM_001278914, NM_001278915, NM_001278916, NM_001278917, NM_001278918, NM_001278939, BC035570, BC050379, BC065566
• Summary: 'This gene encodes a protein that is one of the two components of elastic fibers. Elastic fibers comprise part of the extracellular matrix and confer elasticity to organs and tissues including the heart, skin, lungs, ligaments, and blood vessels. The encoded protein is rich in hydrophobic amino acids such as glycine and proline, which form mobile hydrophobic regions bounded by crosslinks between lysine residues. Degradation products of the encoded protein, known as elastin-derived peptides or elastokines, bind the elastin receptor complex and other receptors and stimulate migration and proliferation of monocytes and skin fibroblasts. Elastokines can also contribute to cancer progression. Deletions and mutations in this gene are associated with supravalvular aortic stenosis (SVAS) and autosomal dominant cutis laxa. [provided by RefSeq, Aug 2017]'
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).